Revolution Medicines (RVMD) News
NASDAQ: RVMDHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
189.76+1.64 (+0.87%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
RVMD news summary
We found 29 recent headlines mentioning Revolution Medicines (RVMD): 1 in the past week and 8 in the past 30 days, most often from Seeking Alpha, Nasdaq, Investing.com. For price context, RVMD is up 0.87% at $189.76. The most recent story, "Why is Revolution Medicines stock sliding today?", was published by Investing.com on Oct 8, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Revolution Medicines headlines
- Why is Revolution Medicines stock sliding today?Investing.com
- Revolution Medicines: Priced For A Label The Trial Didn't Test; HoldSeeking Alpha
- Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?Key PointsRevolution Medicines has just received good news around a drug meant to treat pancreatic cancer.NasdaqRPRX, RVMD
- Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?Key PointsAxsome Therapeutics is generating rapid revenue growth through its expanding portfolio of commercialized central nervous system treatments.NasdaqAXSM, RVMD
- 10 large and mega-cap U.S. healthcare stocks with the strongest momentum gradesSeeking Alpha
- Revolution Medicines Just Hit a Major Milestone. Is the Stock a Buy?Key PointsRevolution Medicines validated its approach to treating certain cancers with a recent regulatory approval.Nasdaq
- Revolution Medicines' Daraxonrasib Secures FDA Breakthrough Designation In Pancreatic Cancer(RTTNews) - Revolution Medicines, Inc. (RVMD), a commercial-stage oncology company developing medicines for RAS-addicted cancers, announced that the U.S. Food and Drug Administration (FDA) has…Nasdaq
- Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?Key PointsAmgen maintains a massive global footprint and generated over $8.1 billion in free cash flow during its latest fiscal year.NasdaqAMGN, RVMD
- Morgan Stanley Initiates Coverage of Revolution Medicines with OverweightFintel reports that on September 10, 2026, Morgan Stanley initiated coverage of Revolution Medicines (NASDAQGS:RVMD) with a Overweight recommendation. Prior to this rating action, the stock closed at…NasdaqRVMD, MS
- Revolution Medicines Got Its Breakthrough—What Moves It Next?Revolution Medicines (NASDAQ: RVMD) just landed one of the biggest wins in oncology this year, and the stock barely blinked. On Aug. 26, the FDA approved RASONQUE (daraxonrasib), the first broad…NasdaqRVMD, LLY, AMGN, MRK
- Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue?Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.NasdaqRVMD, AGIO
- VBK, RVMD, CRDO, CASY: Large Outflows Detected at ETFLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Small-Cap Growth ETF (Symbol: VBK) where we have detected an…NasdaqVBK, RVMD, CRDO, CASY
- Revolution Medicines Highlights NEJM Publication Of RASONQUE Lung Cancer Data(RTTNews) - Revolution Medicines (RVMD), a commercial-stage oncology company, said The New England Journal of Medicine (NEJM) published Phase 1/2 data on RASONQUE (daraxonrasib), its oral RAS(ON)…Nasdaq
- Revolution Medicines: Benefit Vs. Reality Compared To Peer TherapeuticsSeeking Alpha
- Revolution Medicines: Strong Buy RASONQUE FDA Approval And Zoldonrasib PDAC ExpansionsSeeking Alpha
- Revolution Medicines: RASONQUE's FDA Approval Portends A New Oncology TitanSeeking Alpha
- Revolution Medicines Wins FDA Approval for RASONQUE in Metastatic Pancreatic CancerRevolution Medicines (NASDAQ:RVMD) said the U.S. Food and Drug Administration has approved daraxonrasib under the brand name RASONQUE for certain adults with metastatic pancreatic adenocarcinoma. The…Nasdaq
- Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X?Key PointsIt's a cancer medication with immense potential.Nasdaq
- Biotech Stocks At 52-Week Highs - NEO, BLSM, RVMD, ORMP, CADL(RTTNews) - The following biotech stocks reached a 52-week high on August 27, 2026, driven by key catalysts like various regulatory milestones.NasdaqBLSM, CADL, NEO, ORMP
- Revolution Medicines, Inc. (RVMD) Discusses FDA Approval of RASONQUE for Metastatic Pancreatic Cancer and Implications for RAS-Driven Therapy TranscriptSeeking Alpha
- RVMD Secures FDA Win, Gets Nod for Rasonque in Pancreatic CancerRasonque wins FDA approval for pancreatic cancer, giving Revolution Medicines its first marketed product and a commercial foothold.NasdaqRVMD, BMY, SMMT, TNGX
- High Risk, High Reward: Inside The Revolution Medicines Bull CaseSeeking Alpha
- Revolution Medicines, Inc. (RVMD) Q2 2026 Earnings Call TranscriptSeeking Alpha
- Revolution Medicines: Strong Data, Big Market (Rating Upgrade)Seeking Alpha
- Revolution Medicines, Inc. (RVMD) Discusses Positive Clinical Results and Implications for Metastatic Pancreatic Cancer Treatment - SlideshowSeeking Alpha
- Revolution Medicines: More Landmark Data Doesn't Dispel Doubts Around ValuationSeeking Alpha
- Revolution Medicines, Inc. (RVMD) Discusses Positive Clinical Results and Implications for Metastatic Pancreatic Cancer Treatment TranscriptSeeking Alpha
- Revolution Medicines, Inc. (RVMD) Q1 2026 Earnings Call TranscriptSeeking Alpha
- Progress Against Pancreatic Cancer - Part 1Seeking Alpha